-
Something wrong with this record ?
Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade
Vanecková I., Kopkan L., Husková Z., Vanourková Z., Schejbalová S., Cervenka L., Kramer H.J.
Language English Country Switzerland
Grant support
NR8550
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
NLK
Karger Journals
from 1996 to 2009
ProQuest Central
from 1994-05-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2005-01-01
Health & Medicine (ProQuest)
from 1994-05-01 to 1 year ago
ROAD: Directory of Open Access Scholarly Resources
from 1996
- MeSH
- Benzimidazoles pharmacology MeSH
- Angiotensin II Type 1 Receptor Blockers pharmacology MeSH
- Financing, Organized MeSH
- Animals, Genetically Modified MeSH
- Blood Pressure MeSH
- Rats MeSH
- Kidney physiopathology MeSH
- Rats, Sprague-Dawley MeSH
- Proteinuria urine MeSH
- Receptor, Angiotensin, Type 1 metabolism MeSH
- Receptor, Angiotensin, Type 2 physiology blood metabolism MeSH
- Hypertension, Renal drug therapy MeSH
- Renin genetics MeSH
- Tetrazoles pharmacology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second to assess the potential role of AT(2) receptors in the control of blood pressure (BP) in this monogenetic model of hypertension. Male heterozygous TGR and Hannover Sprague-Dawley (HanSD) rats fed a normal salt diet were treated from day 32 of age either persistently until the end of the experiment (day 100 of age) or transiently until day 56 of age with the selective AT(1) receptor antagonist candesartan or with the combination of candesartan and the AT(2) receptor antagonist PD 123319. Persistent treatment with candesartan completely prevented the rise in BP, proteinuria and the increase in left ventricular weight/body weight ratio, whereas transient treatment with candesartan was effective only as long as the drug was administered. In the presence of candesartan, PD 123319 was without effect. Our results show that in male heterozygous TGR persistent candesartan treatment completely prevented hypertension and end-organ damage as long as the drug was administered, whereas transient AT(1 )receptor blockade had no long-term effects. Copyright 2007 S. Karger AG, Basel.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07526849
- 003
- CZ-PrNML
- 005
- 20131007090506.0
- 008
- 090802s2007 sz e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Vaněčková, Ivana, $d 1964- $7 xx0030586
- 245 10
- $a Long-term prevention of hypertension and end-organ damage in Ren-2 transgenic rats is achieved only with persistent but not transient AT1 receptor blockade / $c Vanecková I., Kopkan L., Husková Z., Vanourková Z., Schejbalová S., Cervenka L., Kramer H.J.
- 314 __
- $a Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 520 9_
- $a The aim of this study was first to evaluate the effects of persistent or transient blockade of the angiotensin II (ANG II) receptor AT(1) on the development of hypertension and end-organ damage in hypertensive Ren-2 transgenic rats (TGR), and second to assess the potential role of AT(2) receptors in the control of blood pressure (BP) in this monogenetic model of hypertension. Male heterozygous TGR and Hannover Sprague-Dawley (HanSD) rats fed a normal salt diet were treated from day 32 of age either persistently until the end of the experiment (day 100 of age) or transiently until day 56 of age with the selective AT(1) receptor antagonist candesartan or with the combination of candesartan and the AT(2) receptor antagonist PD 123319. Persistent treatment with candesartan completely prevented the rise in BP, proteinuria and the increase in left ventricular weight/body weight ratio, whereas transient treatment with candesartan was effective only as long as the drug was administered. In the presence of candesartan, PD 123319 was without effect. Our results show that in male heterozygous TGR persistent candesartan treatment completely prevented hypertension and end-organ damage as long as the drug was administered, whereas transient AT(1 )receptor blockade had no long-term effects. Copyright 2007 S. Karger AG, Basel.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a blokátory receptorů AT1 pro angiotensin II $x farmakologie $7 D047228
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a geneticky modifikovaná zvířata $7 D030801
- 650 _2
- $a benzimidazoly $x farmakologie $7 D001562
- 650 _2
- $a krevní tlak $7 D001794
- 650 _2
- $a renální hypertenze $x farmakoterapie $7 D006977
- 650 _2
- $a ledviny $x patofyziologie $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a proteinurie $x moč $7 D011507
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Sprague-Dawley $7 D017207
- 650 _2
- $a receptor angiotensinu typ 1 $x metabolismus $7 D044140
- 650 _2
- $a receptor angiotensinu typ 2 $x fyziologie $x krev $x metabolismus $7 D044139
- 650 _2
- $a renin $x genetika $7 D012083
- 650 _2
- $a tetrazoly $x farmakologie $7 D013777
- 700 1_
- $a Kopkan, Libor $7 xx0107287
- 700 1_
- $a Husková, Zuzana, $d 1978- $7 xx0074206
- 700 1_
- $a Vaňourková, Zdeňka, $d 1973- $7 xx0074217
- 700 1_
- $a Schejbalová, Stanislava $7 xx0134795
- 700 1_
- $a Červenka, Luděk, $d 1967- $7 xx0037105
- 700 1_
- $a Kramer, Herbert J. $7 xx0085908
- 773 0_
- $w MED00003064 $t Kidney & blood pressure research $g Roč. 30, č. 1 (2007), s. 38-44 $x 1420-4096
- 910 __
- $a ABA008 $b x $y 7 $z 0
- 990 __
- $a 20090726182400 $b ABA008
- 991 __
- $a 20131007091027 $b ABA008
- 999 __
- $a ok $b bmc $g 670865 $s 530014
- BAS __
- $a 3
- BMC __
- $a 2007 $b 30 $c 1 $d 38-44 $i 1420-4096 $m Kidney & blood pressure research $x MED00003064
- GRA __
- $a NR8550 $p MZ0
- LZP __
- $a 2009-B3/vtme